Literature DB >> 2039202

Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid.

N Moniot-Ville1, J Guibert, N Moreau, J F Acar, E Collatz, L Gutmann.   

Abstract

Two associated resistance mechanisms were found in a nalidixic acid-susceptible (4 micrograms/ml) but fluoroquinolone-resistant (8 to 16 micrograms/ml) strain of Escherichia coli Q2 selected under norfloxacin therapy. As compared with the susceptible E. coli Q1 isolated before treatment, changes in outer membrane proteins and lipopolysaccharides in Q2 were associated with a 1.5- to 3-fold decrease in the uptake of fluoroquinolones but not nalidixic acid. A 50% inhibition of DNA synthesis in toluene-permeabilized cells of the resistant strain E. coli Q2 required up to 500-fold increased quantities of fluoroquinolones, whereas such inhibition was obtained in both E. coli Q1 and Q2 with similar amounts of nalidixic acid. Selection from E. coli Q1 on norfloxacin of one-step resistant mutants resembling E. coli Q2 was unsuccessful. From these results we infer that a decrease in outer membrane permeability, associated with a peculiar alteration of the DNA gyrase, was responsible for the unusual quinolone resistance phenotype of E. coli Q2.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2039202      PMCID: PMC245042          DOI: 10.1128/AAC.35.3.519

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli.

Authors:  K Hirai; H Aoyama; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

2.  New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity.

Authors:  J Yamagishi; Y Furutani; S Inoue; T Ohue; S Nakamura; M Shimizu
Journal:  J Bacteriol       Date:  1981-11       Impact factor: 3.490

3.  Inhibition of DNA replication in vitro by pefloxacin.

Authors:  B Badet; P Hughes; M Kohiyama; P Forterre
Journal:  FEBS Lett       Date:  1982-08-23       Impact factor: 4.124

4.  Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.

Authors:  D C Hooper; J S Wolfson; K S Souza; C Tung; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

5.  Properties of the penicillin-binding proteins of Escherichia coli K12,.

Authors:  B G Spratt
Journal:  Eur J Biochem       Date:  1977-01

6.  Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.

Authors:  K Hirai; H Aoyama; S Suzue; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

7.  Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.

Authors:  S Inoue; T Ohue; J Yamagishi; S Nakamura; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

8.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

9.  Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels.

Authors:  P J Hitchcock; T M Brown
Journal:  J Bacteriol       Date:  1983-04       Impact factor: 3.490

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more
  24 in total

Review 1.  Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Novel ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus.

Authors:  Laura J V Piddock; Yu Fang Jin; Mark A Webber; Martin J Everett
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

3.  New quinolone resistance phenomenon in Salmonella enterica: nalidixic acid-susceptible isolates with reduced fluoroquinolone susceptibility.

Authors:  Antti J Hakanen; Marianne Lindgren; Pentti Huovinen; Jari Jalava; Anja Siitonen; Pirkko Kotilainen
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Inactivation of efflux pumps abolishes bacterial biofilm formation.

Authors:  Malin Kvist; Viktoria Hancock; Per Klemm
Journal:  Appl Environ Microbiol       Date:  2008-10-03       Impact factor: 4.792

5.  Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.

Authors:  L J Piddock; M Zhu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

6.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 7.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.

Authors:  P Heisig; R Tschorny
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.

Authors:  María Pérez-Vázquez; Federico Román; Belén Aracil; Rafael Cantón; José Campos
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

10.  Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid.

Authors:  E Cambau; F Bordon; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.